AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share

Core Viewpoint - AB Science SA has announced the initiation of coverage of its stock by Maxim Group, with a target price set at €4.00 per share [1][2]. Group 1: Coverage Initiation - Maxim Group has published a study titled "Mastering Mast Cell Inhibition for Neurodegenerative Diseases Starting with ALS," recommending a buy rating for AB Science's stock [2][3]. - The study emphasizes the promising benefits of masitinib across three neurodegenerative diseases, validating the mast cell inhibition approach [3]. Group 2: Financial Analyst Consensus - This initiation of coverage by Maxim Group completes the coverage of AB Science's stock, adding to the consensus from other financial analysts including Chardan, In Extenso Finance, and DNA Finance [4]. Group 3: Company Overview - AB Science, founded in 2001, specializes in the research, development, and commercialization of protein kinase inhibitors (PKIs) targeting diseases with high unmet medical needs [5]. - The company's lead compound, masitinib, is already registered for veterinary medicine and is being developed for human medicine in various fields including oncology and neurological diseases [6].